Arbutus Biopharma (ABUS) Net Cash Flow Growth (1y) (2014 - 2026)
Arbutus Biopharma (ABUS) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 301.06% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 669.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 669.27% |
| Dec 31, 2025 | -197.43% |
| Sep 30, 2025 | 51.56% |
| Jun 30, 2025 | -98.40% |
| Mar 31, 2025 | -95.59% |
| Dec 31, 2024 | -48.32% |
| Sep 30, 2024 | -219.90% |
| Jun 30, 2024 | 247.24% |
| Mar 31, 2024 | 71.83% |
| Dec 31, 2023 | 28.98% |
| Sep 30, 2023 | 58.48% |
| Jun 30, 2023 | 60.67% |
| Mar 31, 2023 | 135.04% |
| Dec 31, 2022 | -78.42% |
| Sep 30, 2022 | -149.69% |
| Jun 30, 2022 | 29.83% |
| Mar 31, 2022 | -202.71% |
| Dec 31, 2021 | 170.11% |
| Sep 30, 2021 | -8.10% |
| Jun 30, 2021 | -348.18% |